english.prescrire.org > Prescrire International > N°135 - February 2013

n°135

February 2013

Issue Contents
Editorial

Free  Malfeasance on an industrial scale

p.32
Pharmacovigilance is mission impossible for pharmaceutical companies

Marketing Authorisations


Argatroban (Additional Market Launch)

p.33-35
For a few selected patients

INN common stem: -oxacin

p.35

Linagliptin (New Drug)

p.36-37
Avoid gliptins!

Prescrire's advice

p.37
Do not include gliptins in your prescribing list

13-valent pneumococcal vaccine: 50 years of age and older (New Indication)

p.38
No proven benefit

Neoadjuvant trastuzumab for breast cancer (New Indication)

p.39
Better to stick with proven treatments

Saxagliptin + metformin (New Combination)

p.40
Mostly disadvantages

Adverse Effects


Dabigatran: life-threatening bleeding

p.41-43
Pharmacovigilance revealed risk factors

SSRI antidepressants: altered psychomotor development following exposure in utero?

p.43-44
During pregnancy non-drug methods should be tried first

Injectable paracetamol in children: yet more cases of 10-fold overdose

p.44-45
Do not mix milligrams and millilitres

Benfluorex: in utero exposure

p.46
Women were given appetite suppressants during pregnancy

Intravenous administration: frequent errors

p.46
Mostly faster administration rate

Everolimus: gastrointestinal haemorrhage

p.46
List of adverse effects growing

Free  An initiative to prevent the adverse effects of metformin

p.47
A collaborative approach

Free  Methylphenidate: abuse in Europe

p.47
Alarming increase in consumption

Free  Benfluorex and cardiac valve disease: long delay in publication

p.47
Unresponsive authorities

Reviews


First-line treatment of metastatic prostate cancer

p.48-51
Androgen suppression for symptomatic disease

Choice of first-line treatment for metastatic prostate cancer

p.51

Outlook


Drugs in wastewater: incomplete removal by treatment plants

p.52-54
One more reason to reduce drug use

The European Union Water Framework Directive (2000)

p.53

The important role of public-sector research in the United States

p.54
A key contributor to the development of new drugs

(Hi)story

p.55
Ceruse: a skin-lightening cosmetic at the king's court

Masthead


Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe